GW273225 Therapy Added To Current Seizure Treatments In Patients With Partial Seizures

GlaxoSmithKline (GSK)

Status and phase: Withdrawn; Phase 2

Conditions: Epilepsy

Treatments: Drug: GW273225

Study type: Interventional

Funder types: Industry

Identifiers

NCT00567424

NEC107055

Details and patient eligibility

About

Study to determine drug interactions between GW273225 and the anticonvulsants valproate, carbamazepine or phenytoin

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Confident diagnosis of epilepsy
• Currently on VPA, CBZ or PHT
• >or= 4 seizures/4 weeks prior to screen

Exclusion criteria

• Prior lamotrigine use (excluded if treatment discontinued for clinically significant safety reasons (i.e., rash, hypersensitivity)).
• Females of childbearing potential on hormonal contraceptives or hormone replacement therapy.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)